title: [Renal accumulation of technetium-99m-labeled bone imaging agents in patients treated with cisplatin].
abstract: As the routine follow-up studies in patients with malignant diseases, bone scintigraphy is often performed to detect bone metastasis, before, during and/or after the treatments. Among these patients who were treated, especially, with CDDP, we often encountered the markedly increased renal radioactivity during the follow-up period by bone scintigraphy. In this study, 68 patients with 76 bone scintigraphy performed within 30 days after the administration of CDDP were evaluated. Forty-five of the 76 bone scintigraphy (60.5%) in the 68 patients exhibited more prominent accumulation of the radionuclide in the kidneys than that normally seen. Among them, twenty-four cases (31.6%) showed markedly increased accumulation of the radionuclide in the kidneys so called the "hot kidneys", when the bone scintigraphy was performed later than 3 weeks after the treatment with CDDP. Moreover, the frequency of the "hot kidneys" were well correlated with the degree of renal damage in terms of serum creatinine levels. These findings suggest that the "hot kidneys" might represent the presence of transient renal damage caused by the administration of CDDP. As the causes of this finding called as the "hot kidneys", various factors and/or many causes are reported recently, however, the highest incidence of this phenomenon is thought to be occurred by CDDP as the factor of drug incidence.
authors.forename: H
authors.initials: H
authors.lastname: Igari
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Fuziwara
authors.forename: K
authors.initials: K
authors.lastname: Watai
authors.forename: M
authors.initials: M
authors.lastname: Kakei
authors.forename: K
authors.initials: K
authors.lastname: Matsui
authors.forename: Y
authors.initials: Y
authors.lastname: Ono
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011877:Radionuclide Imaging; D013669:Technetium Tc 99m Medronate / Q000493:pharmacokinetics*
chemical_list: D002945:Cisplatin; D013669:Technetium Tc 99m Medronate